Radiofreq Ablat for Endocrine/Metabolic: 92.3% of denials overturned
In 13 California IMR decisions from 2021 to 2025, reviewers overturned 12 (92.3%). In the last five years: 92.3% of 13. 6 were medical-necessity disputes, 7 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 2 | 100.0% |
| 2022 | 4 | 100.0% |
| 2023 | 3 | 66.7% |
| 2024 | 1 | 100.0% |
| 2025 | 3 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 7 | 85.7% | 92.3% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for radiofrequency ablation (RFA). Findings: The physician reviewer found that the available treatments for benign non-functioning thyroid nodules include surgical resection, ethanol ablation, and thermal ablation with laser or RFA. According to the American Association of Clinical Endocrinologists (AACE) guidelines, RFA may provide a “less invasive alternative to thyroid surgery, …”
“The physician reviewer found that a patient has requested reimbursement for thyroid radiofrequency ablation (RFA). In this case, the patient was diagnosed with a thyroid nodule with compressive symptoms. A biopsy did not show evidence of malignancy. The patient selected RFA as treatment for her thyroid nodule due to a preference for a non-invasive procedure, as surgical intervention required general …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for thyroid radiofrequency ablation (RFA). Studies demonstrate that RFA consistently reduces nodule volume, with median volume reduction rates of 50-76% at 12 months and sustained efficacy up to five years. Solid or predominantly solid, or mixed solid-cystic nodules respond well to RFA. Moreover, the American …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for radiofrequency ablation of thyroid nodule on the right side. A review of the current medical literature pertaining to the use of radiofrequency ablation reveals that despite some support regarding its effectiveness in reducing the size of benign nodules, the literature concentrates mostly on smaller nodules and cystic …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Radiofreq Ablat denials for Endocrine/Metabolic overturned?
In 13 California IMR decisions from 2021 to 2025, reviewers overturned 12 (92.3%). In the last five years: 92.3% of 13. 6 were medical-necessity disputes, 7 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.